EUVIMEDEUVIMED entdecken
Crossref

AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis

Burcak Ozes iD, Lingying Tong, Morgan Myers, Kyle Moss, Edward Son iD, Tatyana A Vetter iD, Gabriela Vasquez-Martinez, Diana Zepeda-Orozco, Zarife Sahenk iD

Human Gene Therapy · 2026

DOI: 10.1177/10430342261466685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Burcak Ozes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Myositis, Inclusion Body, Genetic Therapy, Valosin Containing Protein, Dependovirus. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the valosin-containing protein (VCP) gene lead to a hereditary type of inclusion body myositis (hIBM), in which sarcoplasmic and myonuclear inclusions with TAR DNA-binding protein 43 (TDP-43) pathology and mitochondrial abnormalities are observed in histological analysis. Pathophysiological conditions in the cell cause the protein quality control system to depend on the autophagy-lysosome pathway (ALP) for degradation of accumulated misfolded proteins and mitochondrial turnover. BCL2-associated athanogene 3 (BAG3) protein has a role in initiating the ALP. Our aim was to ameliorate disease processes resulting from mitochondrial abnormalities and misfolded protein aggregation by upregulating the ALP through overexpression of human BAG3 (hBAG3). The VCP-A232E mouse, a model for hIBM, received AAVrh74.tMCK.hBAG3 systemically at 3 months of age, and outcome measures, including functional, histological, and molecular studies, were assessed 9 months post-gene delivery. hBAG3 treatment improved treadmill running distance and rotarod duration, reduced the number of TDP-43-positive aggregates, and decreased the number of fibers showing abnormalities in mitochondrial enzyme histochemistry, compared with the untreated cohort. Moreover, hBAG3 gene therapy resulted in improvements in mitophagy and mitochondrial homeostasis observed as increased levels in mitophagy markers Parkin and Bnip3, mitochondria biogenesis marker Pgc1α and mitochondrial DNA-encoded subunits of complex IV, Cox1 and Cox3 . In addition, the LC-II/I ratio increased, indicating increased autophagic flux. Our study presents evidence that the strategy of supporting the ALP system by overexpressing BAG3 has potential therapeutic use for myodegenerative conditions associated with abnormal protein aggregates and mitochondrial turnover.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myositis, Inclusion BodyGenetic TherapyValosin Containing ProteinDependovirusAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsAnimalsDisease Models, AnimalMiceHumansPhenotypeAutophagyGene Therapy AgentsGenetic VectorsMitochondriaDNA-Binding Proteins

Stichwörter der Autor:innen

BAG3IBMVCPautophagymitophagy

Substanzen

Valosin Containing ProteinAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsBAG3 protein, humanBag3 protein, mouseDNA-Binding Proteins

Autor:innen und Institutionen

  • Center for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Kidney and Urinary Tract Research Center, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pediatrics and Neurology, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.

ORCID-Profile: Burcak Ozes, Edward Son, Tatyana A Vetter, Zarife Sahenk

Zitieren

APA

Ozes, B., Tong, L., Myers, M., Moss, K., Son, E., Vetter, T. A., Vasquez-Martinez, G., Zepeda-Orozco, D., & Sahenk, Z. (2026). AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis. Human Gene Therapy. https://doi.org/10.1177/10430342261466685

Vancouver

Ozes B, Tong L, Myers M, Moss K, Son E, Vetter TA, et al. AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis. Human Gene Therapy. 2026. doi:10.1177/10430342261466685

BibTeX
@article{Ozes2026,
  author = {Ozes, Burcak and Tong, Lingying and Myers, Morgan and Moss, Kyle and Son, Edward and Vetter, Tatyana A and Vasquez-Martinez, Gabriela and Zepeda-Orozco, Diana and Sahenk, Zarife},
  title = {AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261466685}
}
Kostenlos starten →